Latest News for GNTA

MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry…

Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies ATC - a Defense-Sector Company: First Industrial Integration Praexidia Foundation Joins as a Long-Term Strategic Shareholder Corporate Name Change to Saentra Forge S.p.A. Biotech Clinical Updates and Partnering Strategy Cash, Cash Equivalents, and Marketable…

MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi. Over time, Mr.

Genenta Science S.p.A. Unsponsored ADR (NASDAQ: GNTA - Get Free Report)'s share price rose 0.7% during mid-day trading on Monday. The stock traded as high as $1.61 and last traded at $1.42. Approximately 376,116 shares changed hands during trading, an increase of 262% from the average daily volume of 103,829 shares. The stock had previously
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GNTA.
U.S. House Trading
No House trades found for GNTA.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
